Tirzepatide (the active ingredient in Zepbound) is still under patent protection, which means branded pricing is the reality for now — but the landscape will shift, and here's what to expect.
How pharmaceutical patents work:
When could prices drop?
Tirzepatide's core patents are expected to begin expiring in the mid-2030s, though the exact timeline depends on patent extensions, litigation, and regulatory decisions that are difficult to predict. Generic entry typically follows patent expiry by a year or more.
What's available in the meantime:
The short answer: meaningful generic competition for tirzepatide is likely still a decade away. **Talk to your provider** about savings programs and compounding options that may be available to you today.
Different ways people phrase this question. Each expands to the same answer.
Tirzepatide (the active ingredient in Zepbound) is still under patent protection, which means branded pricing is the reality for now — but the landscape will shift, and here's what to expect.
How pharmaceutical patents work:
When could prices drop?
Tirzepatide's core patents are expected to begin expiring in the mid-2030s, though the exact timeline depends on patent extensions, litigation, and regulatory decisions that are difficult to predict. Generic entry typically follows patent expiry by a year or more.
What's available in the meantime:
The short answer: meaningful generic competition for tirzepatide is likely still a decade away. **Talk to your provider** about savings programs and compounding options that may be available to you today.
Tirzepatide (the active ingredient in Zepbound) is still under patent protection, which means branded pricing is the reality for now — but the landscape will shift, and here's what to expect.
How pharmaceutical patents work:
When could prices drop?
Tirzepatide's core patents are expected to begin expiring in the mid-2030s, though the exact timeline depends on patent extensions, litigation, and regulatory decisions that are difficult to predict. Generic entry typically follows patent expiry by a year or more.
What's available in the meantime:
The short answer: meaningful generic competition for tirzepatide is likely still a decade away. **Talk to your provider** about savings programs and compounding options that may be available to you today.
Tirzepatide (the active ingredient in Zepbound) is still under patent protection, which means branded pricing is the reality for now — but the landscape will shift, and here's what to expect.
How pharmaceutical patents work:
When could prices drop?
Tirzepatide's core patents are expected to begin expiring in the mid-2030s, though the exact timeline depends on patent extensions, litigation, and regulatory decisions that are difficult to predict. Generic entry typically follows patent expiry by a year or more.
What's available in the meantime:
The short answer: meaningful generic competition for tirzepatide is likely still a decade away. **Talk to your provider** about savings programs and compounding options that may be available to you today.